An interventional study of High-frequency chest wall oscillation (HFCWO) vest and Mechanical cough assist in Amyotrophic Lateral Sclerosis and Respiratory Infection, sponsored by Hospital Universitario Virgen Macarena. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Hospital Universitario Virgen Macarena · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain — 11 open to participants now, 16 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Spain.
Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, this one is the 48th largest by enrollment of the 51 interventional ones that give a count, is one of 12 that started in 2021, is one of 6 with no phase, and was the 55th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →11 of the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, Belgium, Canada and 2 more countries
Ages 18–80
Eli Lilly and Company · Sites in Spain, Belgium, Canada and 2 more countries
Ages 18–80
Prilenia · Sites in Spain, United States, Belgium and 10 more countries
Ages 18–80
PhenoNet, Inc. · Sites in Spain, United States, Czechia and 3 more countries
Ages 18–75
Biogipuzkoa Health Research Institute · Sites in Spain
Ages 18–75
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 19 · Phase 3 24
First in 2007; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 227 across the 51 interventional studies, 60 across the 5 observational. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 56 have an industry lead sponsor. The 10 most frequent:
Hospital Universitario Virgen Macarena is the lead sponsor of 18 studies on the registry; 5 are open to participants now.
Hospital Universitario Virgen Macarena has 1 study filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Amyotrophic Lateral Sclerosis with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07414212Biogipuzkoa Health Research InstituteEvaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) | 2026-11-25 |
| NCT07142291PhenoNet, Inc.PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | 2027-03 |
| NCT07100119Eli Lilly and CompanyA Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis | 2027-08 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This pilot randomised single-blind trial evaluated whether adding high-frequency chest wall oscillation (HFCWO) via chest vest (ComfortCough II) to mechanical cough assist improves respiratory outcomes and reduces respiratory infections and hospital admissions compared to mechanical cough assist alone in patients with amyotrophic lateral sclerosis (ALS) receiving non-invasive ventilation.
Patients with amyotrophic lateral sclerosis (ALS) receiving non-invasive ventilation (NIV) at the Multidisciplinary ALS Unit of Hospital Universitario Virgen Macarena (Seville, Spain) were randomised to two parallel groups. The experimental group received high-frequency chest wall oscillation (HFCWO) via chest vest (ComfortCough II/CC20) combined with mechanical cough assist, while the control group received mechanical cough assist alone. The intervention period lasted 3 months, followed by 3 months of follow-up. Primary outcomes included respiratory infections and hospital admissions. Secondary outcomes included respiratory function, quality of life, sleep quality, and secretion clearance capacity. The study was approved by the Ethics Committee of Hospital Universitario Virgen Macarena - Virgen del Rocío (code 2020-01) and sponsored by FISEVI (Fundación Pública Andaluza para la Investigación Biosanitaria de Andalucía).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
exclusion criteria:
Patients received high-frequency chest wall oscillation via chest vest (ComfortCough II) combined with mechanical cough assist for 3 months followed by 3 months follow-up.
Device: High-frequency chest wall oscillation (HFCWO) vest · Device: Mechanical cough assist
Patients received mechanical cough assist alone for 3 months followed by 3 months follow-up.
Device: Mechanical cough assist
Chest wall oscillation vest delivering high-frequency vibrations to mobilise secretions, used in addition to mechanical cough assist device during the 3-month intervention period.
Also known as: ComfortCough II , CC20
Mechanical insufflation-exsufflation device used alone for airway secretion clearance during the 3-month intervention period.
Also known as: Cough assist device
Number of respiratory infections
Number of respiratory infections requiring antibiotic treatment during the study period
Time frame: 6 months (3 months intervention plus 3 months follow-up)
Number of hospital admissions
Number of hospital admissions due to respiratory causes during the study period
Time frame: 6 months (3 months intervention plus 3 months follow-up)
Forced Vital Capacity (FVC)
Change in forced vital capacity percentage from baseline
Time frame: 6 months
Peak Cough Flow (PCF)
Change in peak cough flow from baseline
Time frame: 6 months
Gait analysis
Change in gait parameters assessed by GAITRite electronic walkway system and correlation with respiratory function (FVC)
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2021 to primary completion in Nov 2023, 30 months.
Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 30 months is below that.
Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →
Hospital Universitario Virgen Macarena